Viewing Study NCT06578559

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:46 PM
Ignite Modification Date: 2026-01-28 @ 12:31 PM
Study NCT ID: NCT06578559
Status: RECRUITING
Last Update Posted: 2025-04-18
First Post: 2024-07-29
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
Sponsor: Gruppo Oncologico del Nord-Ovest
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Colorectal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ctDNA View
None Encorafenib View
None Cetuximab View
None rechallenge View
None retreatment View
None BRAF V600E View